Home|Journals|Articles by Year|Audio Abstracts

Review Article

SRP. 2020; 11(11): 117-128

SIRTUIN 1, a novel approach in the treatment of type 2 diabetes mellitus

Rusul Ahmed Tariq, Inam Sameh Arif, Basma Talib Al-Sudani.


Type 2 diabetes mellitus (T2DM) was a chronic metabolic disorder in which prevalence has been increasing progressively all over the world. The innovate therapeutic approaches against T2DM are required in order to inhibit and treat T2DM. On the other hand, previous research has proven that activation of SIRT1 might prevent T2DM, demonstrating the SIRT1 may consider as a novel curative target for T2DM treatment. So, in this study, SIRT1 aptamer as activator of SIRT1enzyme was used as a pharmacological model to prevent T2DM by management the expression of SIRT1, FOXO3a and PGC-1α, genes in INS-1 832/13 rat insulinoma high fat cell lines (a type of model that used in order to study the pancreatic islet beta-cell role and for insulin excretion organization). The outcomes of RT-PCR showed that 10 µM of SIRT1 aptamer can up regulates PGC-1α, SIRT1 and FOXO3a expression in rat insulinoma cell lines. Moreover, the outcomes of western blot showed that palmitic acid (PA) modified the expression of lipid metabolism‑related genes and mitochondrial biogenesis-related, while SIRT1 aptamer treatment improvement the PA that prompted alterations in the expression of previous genes through SIRT1. To sum up, this study provides important information regarding the effect of SIRT1 aptamer on modifiable the expression of mitochondrial genes related with biogenesis. So, SIRT1 aptamer may be considered as a prospective future therapy for mitigates T2DM.

Key words: SIRT1, aptamer, FOXO, Gene expression, RT-PCR.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com
• ojshosting.net

Do you want to use OJS for your journal ?
work with an experienced partner

Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.